Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
WHO Expert Committee on Drug Dependence – WHO Technical Report Series, No. 915 – Thirty-third Report
(2003; 31 pages) [French] [Spanish] View the PDF document
Table of Contents
View the document1. Introduction
View the document2. Scheduling criteria
Open this folder and view contents3. Critical review of psychoactive substances
Open this folder and view contents4. Pre-review of psychoactive substances
View the document5. Terminology used in reporting abuse-related adverse drug reactions
View the document6. Other matters
View the documentAcknowledgements
View the documentReferences
View the documentAnnex Terminology used in reporting abuse-related adverse drug reactions
 

WHO Expert Committee on Drug Dependence – WHO Technical Report Series, No. 915 – Thirty-third Report


World Health Organization
Geneva 2003

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization

WHO Library Cataloguing-in-Publication Data

WHO Expert Committee on Drug Dependence (2002: Geneva, Switzerland)

WHO Expert Committee on Drug Dependence: thirty-third report.

(WHO technical report series; 915)

1. Psychotropic drugs - classification 2. Psychotropic drugs - pharmacology 3. Drug and narcotic control 4. Treaties 5. Guidelines I. Title II. Series.

ISBN 92 4 120915 1 (NLM classification: WM 270)
ISSN 0512-3054

© World Health Organization 2003

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Typeset in Hong Kong
Printed in Singapore

WHO Expert Committee on Drug Dependence
Geneva, 17-20 September 2002

Members

Professor M.S. Bourin, Department of Pharmacology, Faculty of Medicine, University of Nantes, Nantes, France

Professor Cai Zhiji, Honorary Director, National Institute on Drug Dependence, Beijing, People’s Republic of China

Dr L. De Lima, MD Anderson Cancer Center, University of Texas, Houston, TX, USA

Professor A.S. Elmi, Consultant, Rexdale Health Centre, Toronto, Ontario, Canada

Dr S. Haghighi, Deputy Director for Production, Pasteur Institute of Iran, Farvardin, Islamic Republic of Iran

Dr E.M.A. Ombaka, Director, Ecumenical Pharmaceutical Network, Westlands, Nairobi, Kenya

Professor C.R. Schuster, Director, Substance Abuse Research Division & Addiction Research Institute, Wayne State University, Department of Psychiatry and Behavioral Neurosciences, Detroit, MI, USA (Rapporteur)

Professor S. Suryawati, Head, Department of Clinical Pharmacology, Faculty of Medicine, Gadjah Mada University, Yogyakarta, Indonesia

Professor T. Suzuki, Department of Toxicology, School of Pharmacy, Hoshi University, Tokyo, Japan

Professor W. Wieniawski, Chairman, Polish Pharmacopoeia Commission, Warsaw, Poland (Chairman)

Representatives of other organizations

Consumers International (CI/IOCU)
Mr C. Medawar, Consumers International, London, England

International Federation of Pharmaceutical Manufacturers Associations (IFPMA)
Dr W. Erni, International Federation of Pharmaceutical Manufacturers Associations, Geneva, Switzerland

International Narcotics Control Board (INCB)
Dr E.L.A. Carlini, Member, International Narcotics Control Board, Vienna, Austria

United Nations International Drug Control Programme (UNDCP)
Dr B. Remberg, Scientific Expert, United Nations International Drug Control Programme, Vienna, Austria

Dr J. Tomas-Rossello, Expert in Drug Abuse Treatment, United Nations International Drug Control Programme, Vienna, Austria

World Self-Medication Industry (WSMI)

Dr J.A. Reinstein, Director-General, World Self-Medication Industry, London, England

Secretariat

Dr R. Edwards, Director, Uppsala Monitoring Centre, Uppsala, Sweden (Temporary Adviser)

Mr S. Elliott, Regional Laboratory for Toxicology, City Hospital NHS Trust, Birmingham, England (Temporary Adviser)

Dr L. Rägo, Coordinator, Quality Assurance and Safety: Medicines, Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland

Mr T. Yoshida, Scientist, Quality Assurance and Safety: Medicines, Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland (Secretary)

to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: August 29, 2014